MRx-4DP0004 is a biologic commercialized by 4D Pharma, with a leading Phase II program in Asthma. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MRx-4DP0004’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for MRx-4DP0004 is expected to reach an annual total of $108 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

MRx-4DP0004 Overview

MRx-4DP0004 is under development for the treatment of severe neutrophilic asthma. The therapeutic candidate is administered through oral route. It constitutes naturally occurring single strain live bacteria. It is developed based on MicroRx technology.

It was also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

4D Pharma Overview

4D Pharma formerly 4D Pharma Ltd, is a drug development company. The company discovers and develops bio therapeutics and therapies for the treatment of cancer, gastro-intestinal, autoimmune and CNS diseases. Its pipeline product candidates include MRx0518, a neoadjuvant monotherapy for solid tumors and pancreatic cancer; Blautix, for the treatment of irritable bowel syndrome; MRx-4DP0004 against allergic asthma and coronavirus; and MRx0029 to treat neurodegeneration. It is also evaluating therapies in the areas of oncology, gastro-intestinal, respiratory, and other therapeutic areas. 4D Pharma also offers clinical development services. The company has operational presence in Ireland and Spain. 4D Pharma is headquartered in Leeds, Yorkshire, the UK.

The company reported revenues of (British Pounds) GBP0.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 2.2% over FY2020. The operating loss of the company was GBP70.5 million in FY2021, compared to an operating loss of GBP30.2 million in FY2020. The net loss of the company was GBP54 million in FY2021, compared to a net loss of GBP26 million in FY2020.

For a complete picture of MRx-4DP0004’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.